Drug Database
SH

SH-U-454

✓ Approved

Bayer AG · Small Molecule · Small Molecule

What is SH-U-454?

SH-U-454 is a small molecule developed by Bayer AG. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyBayer AG
Drug ClassSmall Molecule, Imaging Agents
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, Bayer AG

Therapeutic Indications

SH-U-454 is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Cardiac disordersArteriosclerosis coronary artery✓ Approved

Related Research Articles

PubMedJournal of the American Heart Association2026-07-17

Association Between Pregnancy and Symptomatic Hemorrhage in Women With Brainstem Cavernous Malformations and Bleeding in the Preceding Year: A Prospective Multicenter Study.

Zheng Jing-Jie JJ, Weng Jian-Cong JC, Xu Xiao-Ying XY, Guo Jia J et al.

The association between pregnancy and the risk of symptomatic hemorrhage (SH) in brainstem cavernous malformations remains uncertain. We aimed to quantify the risk of pregnancy-associated SH in women with brainstem cavernous malformations. We analyzed women with brainstem cavernous malformations in a prospective registry (2016-2022) experiencing pregnancy after enrollment. Follow-up was divided into pregnancy-associated segments (pregnancy plus ≤6 weeks postpartum or postabortion) and nonpregnant segments. Primary analysis used case-crossover models; propensity score-matched analyses assessed robustness. Among 63 women (median age, 30.0 years), 53 (84.1%) had bled before enrollment, including 45 (71.4%) with SH in the preceding year. Prospectively, they contributed 72 pregnancies and 371.7 patient-years, observing 34 SHs. The pregnancy annual SH rate was 20.4% versus 7.2% nonpregnant (adjusted incidence rate ratio: 2.56, 95% CI, 1.11-5.93; P=0.028). Trimester-specific and postpartum annual SH rates were 5.9%, 16.8%, 34.6%, and 38.3%; risk significantly increased only during the third trimester (P=0.004) and postpartum (P=0.007). This pregnancy effect was confined to segments with SH in the preceding year (annual SH rates 46.7% versus 9.4%; P=0.007), which was an independent risk factor. Propensity score-matched analyses yielded consistent results. Pregnancy is associated with an elevated SH risk in women with brainstem cavernous malformations, specifically among those with SH in the preceding year. Because of selection bias, generalizability to asymptomatic or incidental lesions is limited, warranting cautious extrapolation. URL: www.chictr.org.cn; Unique Identifier: ChiCTR-POC-17011575.

PMID 42466515
Read full article →
PubMedAngewandte Chemie (International ed. in English)2026-07-17

Engineered Substrates for a Sulfurtransferase Enhance Endogenous Hydropersulfides and Inhibit Ferroptosis.

Gupta Simran M SM, Duraisamy Santhosh S, Takata Tsuyoshi T, Akaike Takaaki T et al.

Cellular hydropersulfides (RS-SH) derived from hydrogen sulfide (H2S) such as glutathione hydropersulfide (GS-SH) are excellent hydrogen atom transfer agents, and quench radicals to protect cells from ferroptosis, a form of iron-mediated cell death associated with an unchecked build-up of lipid radicals. Here, using principles of enzyme-inhibitor design, a series of new artificial substrates for the endogenous hydropersulfide-generating enzyme, 3-mercaptopyruvate sulfurtransferase (3-MST) was developed. We find that the lead molecules generated GS-SH, catalyzed by 3-MST, permeated cells to enhance endogenous hydropersulfides, protected cells from ferroptosis, and reduced systemic inflammation in an animal model. Together, this calibrated approach to promote cell's own radical trapping antioxidants using its biosynthetic machinery to prevent ferroptosis has tremendous implications in redox biology and therapeutics.

PMID 42466747
Read full article →
PubMedFrontiers in oncology2026-07-17

Repurposing tricyclic drugs as cancer therapeutics: comparative analysis of antitumorigenic effects of chlorpromazine, amitriptyline and imipramine.

Berghausen Joos J, Glasgow Eric E, Brelidze Tinatin I TI

Tricyclic drugs such as chlorpromazine (CPZ), amitriptyline (AmiT), and imipramine (ImiP) have demonstrated antitumorigenic potential, yet their relative potency and selectivity for different tumors remain unclear. Here, we conducted a comparative study of the antitumorigenic effects of these drugs on three major cancer types: breast cancer (MDA-MB-231), neuroblastoma (SH-SY5Y), and melanoma (A375). In vitro antitumorgenic effects were assessed using CellTiter-Blue viability assays and wound-healing assays, while in vivo effects were evaluated using zebrafish xenografts. Cancer cell growth inhibition and migration were examined across all three cancer cell lines following treatment with CPZ, AmiT, or ImiP. In the in vitro experiments, inhibition of cancer cell growth was strongest for CPZ and weakest for ImiP, with AmiT showing intermediate effects across all three cell lines. In wound-healing assays, all three drugs significantly impaired migration in MDA-MB-231 and SH-SY5Y cells but had no effect on the migration of A375 cells. In the in vivo experiments, CPZ and AmiT significantly reduced tumor growth in MDA-MB-231 and SH-SY5Y xenografts, whereas ImiP inhibited tumor growth in a statistically significant manner only for MDA-MB-231 xenografts and did not inhibit tumor growth in SH-SY5Y xenografts. All three drugs failed to inhibit tumor growth in A375 xenografts. Together, these findings demonstrate clear differences in antitumorigenic potency and cancer-type sensitivity among the tested tricyclic drugs, with CPZ being the most potent in both MDA-MB-231 and SH-SY5Y cells, followed by AmiT and then ImiP, in both in vitro and in vivo experiments. In contrast, all three drugs exhibited little or no antitumorigenic effect on A375 cells in both in vitro and in vivo experiments.. These findings further the efforts to repurpose the FDA-approved tricyclic drugs CPZ, AmiT, and ImiP for cancer treatment.

PMID 42465580
Read full article →
PubMedIndian journal of urology : IJU : journal of the Urological Society of India2026-07-17

Bilateral ureteral reconstruction with U-shaped ileal interposition segment.

Eskenazi Federico F, Dugarte Juan Pablo JP, Aron Monish M

We describe a robotic technique for bilateral ureteral reconstruction using a U-shaped ileal interposition in the setting of retroperitoneal fibrosis and vascular encasement. A 77-year-old man with chronic kidney disease, prior orchiectomy with retroperitoneal radiation for testicular cancer, radical prostatectomy, and spine surgery, presented with retroperitoneal fibrosis, bilateral mid-ureteral strictures, and nephrostomy dependence. After adhesiolysis, both ureters were identified at the pelvic brim, dissected off the great vessels, and proximally spatulated. A 25-cm ileal segment was isolated, configured in a U-shape, and anastomosed to the bladder dome at its apex. Each ureter was reimplanted mucosa-to-mucosa to a separate ileal limb over double-J stents, with additional single-J stents placed across the vesico-ileal anastomosis.

PMID 42465784
Read full article →
PubMedBioorganic chemistry2026-07-17

Rational design and synthesis of dispiroindene-pyrrolidinedione scaffolds as multi-target directed ligands: potent AChE inhibitors with antioxidant activity and favorable biocompatibility in SH-SY5Y cells.

Morsy Nagy A NA, El-Shiekh Riham A RA, Ebrahium Mohamad M MM, Srour Aladdin M AM

Addressing the urgent need for multi-target therapies in Alzheimer's disease, we report the rational design and one-pot, multi-component synthesis of novel substituted dispiroindene-pyrrolidinedione scaffolds (4a-r). Systematic biological evaluation identified five lead compounds (4g, 4j, 4k, 4m, and 4p) with potent inhibitory activity. Derivative 4k emerged as the primary lead, exhibiting an IC50 for Acetylcholinesterase (AChE) of 2.58 ± 0.11 μM and a remarkable selectivity index of 15.71, significantly exceeding that of donepezil (4.37), the reference drug. Concurrently, the series demonstrated notable affinity for Butyrylcholinesterase (BChE), with several derivatives exhibiting submicromolar to low micromolar inhibition. Furthermore, these scaffolds demonstrated superior antioxidant potential; notably, compound 4p achieved an IC50 value of 25.23 ± 1.25 μM, demonstrating an approximate 5-fold increase in radical scavenging potency relative to ascorbic acid (128.20 μM). In vitro safety assays on SH-SY5Y human neuroblastoma cells confirmed excellent biocompatibility, with compound 4m displaying an IC50 of 125.00 ± 6.91 μM, nearly four times less toxic than donepezil (32.84 μM). Molecular docking validated these results, showing robust π-π stacking and halogen-based stabilization within the catalytic anionic site. These findings, supported by ADME profiles predicting high blood-brain barrier permeability, position the dispiroindene-pyrrolidinedione framework as a highly effective, low-toxicity, multi-functional candidate for the development of Alzheimer's disease therapeutics.

PMID 42462519
Read full article →
PubMedInternational journal of molecular medicine2026-07-17

Cepharanthine inhibits tick‑borne encephalitis virus infection through modulation of the stress and inflammation response.

Tang Wan-Da WD, Zhao Lan-Juan LJ

Cepharanthine is a potential candidate for developing antiviral agents against tick‑borne encephalitis virus (TBEV), which is a major cause of arboviral neuroinvasive diseases in humans. Cepharanthine is the only bisbenzylisoquinoline alkaloid for treating human diseases due to its unique pharmacological properties. Management of endoplasmic reticulum stress and inflammation response is implicated in therapeutic strategies for TBEV infection. The present study aimed to explore the antiviral efficacy and underlying mechanisms of cepharanthine against TBEV in human lung adenocarcinoma A549 cells and neuroblastoma SH‑SY5Y cells. In co‑treatment and pre‑treatment schemes, cepharanthine exhibited a potent inhibitory effect on TBEV propagation. The antiviral effect of cepharanthine was evidenced by a reduction in TBEV RNA replication, viral protein expression and infectious virus release. The levels of inflammatory cytokines, including tumor necrosis factor‑α, interleukin (IL‑) 1β and IL‑11, induced by TBEV infection were markedly decreased in A549 cells treated with cepharanthine. The induction of IL‑11 was impaired in infected SH‑SY5Y cells treated with cepharanthine. TBEV infection upregulated the expression of C/EBP homologous protein, which was downregulated by cepharanthine treatment. Phosphorylation of eukaryotic initiation factor 2α was enhanced upon cepharanthine treatment during TBEV infection. These in vitro results demonstrated that cepharanthine possesses anti‑TBEV efficacy and that modulation of the stress and inflammation response by cepharanthine may be involved in antiviral mechanisms. The results of the present study support further investigation of cepharanthine as an antiviral agent against TBEV.

PMID 42464660
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about SH-U-454